Pharmacogenetics of drug-induced liver injury

Pharmacogenetics of drug-induced liver injury - DILI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38286

Enrollment

325

Registered

2010-02-19

Start date

2011-02-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-induced liver injury

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age >=18 an ALT > 5 x upper limit of normal (ULN) (or AST when ALT is unavailable) or an ALP > 2 x ULN (especially when associated with 5'-nucleotidase or gamma-glutamyl transpeptidase elevations and when there is no bony cause for rise in ALP) or an ALT > 3 x ULN plus bilirubin > 2 x ULN

Exclusion criteria

Exclusion criteria: see inclusion criteria

Design outcomes

Primary

Measure	Time frame
Variations in metabolic and immune genes between patients with drug-induced liver injury and controls with no liver injury will be studied. Other variables are patient characteristics like age and weight, alcohol and (recreational) drug use.	—

Secondary

Measure	Time frame
None	—

Countries

Netherlands

Outcome results